Sayeh Tadayon
Overview
Explore the profile of Sayeh Tadayon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway F, Jensen C, et al.
JAMA
. 2021 Mar;
325(14):1414-1425.
PMID: 33755728
Importance: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. Objective: To...
2.
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D
Diabetes Obes Metab
. 2020 Dec;
23(3):754-762.
PMID: 33269530
Aim: To investigate the effects of once-weekly subcutaneous (s.c.) semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity. Materials And Methods: A double-blind, parallel-group trial...
3.
Mann J, Hansen T, Idorn T, Leiter L, Marso S, Rossing P, et al.
Lancet Diabetes Endocrinol
. 2020 Sep;
8(11):880-893.
PMID: 32971040
Background: Patients with type 2 diabetes have a high risk of developing chronic kidney disease. We examined the effects of semaglutide on kidney function and safety in a large, broad...
4.
Aroda V, Capehorn M, Chaykin L, Frias J, Lausvig N, Macura S, et al.
Diabetes Obes Metab
. 2019 Oct;
22(3):303-314.
PMID: 31608552
Aim: To evaluate the impact of relevant patient-level characteristics on the efficacy and safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials And Methods: Exploratory post hoc...
5.
Jendle J, Birkenfeld A, Polonsky W, Silver R, Uusinarkaus K, Hansen T, et al.
Diabetes Obes Metab
. 2019 Jun;
21(10):2315-2326.
PMID: 31215727
Aim: To investigate treatment satisfaction with semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, versus placebo/active comparators in the SUSTAIN clinical trial programme. Methods: In SUSTAIN 2-5 and 7, the Diabetes...